A Safety and Immunogenicity Trial of IHV01

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
HIV Infection
Interventions
BIOLOGICAL

300 ug FLSC vaccine

FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168

BIOLOGICAL

150 ug FLSC vaccine

FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168

BIOLOGICAL

75 ug FLSC vaccine

FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168

BIOLOGICAL

Placebo

Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168

Trial Locations (1)

21201

University of Maryland, Institute of Human Virology, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Auro Vaccines LLC

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT02756208 - A Safety and Immunogenicity Trial of IHV01 | Biotech Hunter | Biotech Hunter